The NIH and Moderna Are Fighting Over Who Owns Their Vaccine; Intelligencer, November 10, 2021

Matt Stieb, Intelligencer; The NIH and Moderna Are Fighting Over Who Owns Their Vaccine

"While last year the government was calling the shot the “NIH-Moderna COVID-19 vaccine,” the biotech giant filed a patent made public this week in which it found that “only Moderna’s scientists” designed the vaccine. The patent, filed in July, is specific to the genetic sequence creating spike proteins, which allow vaccine recipients to build antibodies to block the virus when the body is actually exposed. As the New York Times reports, the NIH was surprised by the attempt at a solo effort. If the two parties cannot figure out a way to split the credit, the government will have to determine if it will take the expensive step of going to court. Already, the U.S. has paid $10 billion in taxpayer funds for Moderna to help create the vaccine, test its efficacy, and provide shots for the federal government."

Navy Official: Concerns About Intellectual Property Rights Becoming More 'Acute'; National Defense, NDIA's Business & Technology Magazine, November 29, 2018

Connie Lee, National Defense, NDIA's Business & Technology Magazine;

Navy Official: Concerns About Intellectual Property Rights Becoming More 'Acute'

"Capt. Samuel Pennington, major program manager for surface training systems, said the fear of losing data rights can sometimes make companies reluctant to work with the government.
“We get feedback sometimes where they’re not willing to bid on a contract where we have full data rights,” he said. “Industry [is] not going to do that because they have their secret sauce and they don’t want to release it.”
Pennington said having IP rights would allow the Defense Department to more easily modernize and sustain equipment.
“Our initiative is to get as much data rights, or buy a new product that has open architecture to the point where [the] data rights that we do have are sufficient, where we can recompete that down the road,” he said. This would prevent the Navy from relying on the original manufacturer for future work on the system, he noted.
The issue is also being discussed on Capitol Hill, Merritt added. The fiscal year 2018 National Defense Authorization Act requires the Pentagon to develop policy on the acquisition or licensing of intellectual property. Additionally, the NDAA requires the department to negotiate a price for technical data rights of major weapon systems."

One Way To Force Down Drug Prices: Have The U.S. Exercise Its Patent Rights; NPR, March 16, 2017

Alison Kodjak, NPR; 

One Way To Force Down Drug Prices: Have The U.S. Exercise Its Patent Rights

"...Trump already has a weapon he could deploy to cut the prices of at least some expensive medications.

That weapon is called "march-in rights."...

...[L]ower prices could also make drug companies less eager to invest lots of money in new medications.

That's the trade-off the government has always had to wrestle with. But it's one Trump could very well decide is worthwhile.

"Perhaps we as a country would rather have lower drug prices and a little less innovation," [Sara Fisher] Ellison [an economist at MIT] said."